Generated September 2, 2026 at 8:30 PM ET
· Covers September 2 trading day
· 10 of 186 ready 8-Ks selected
· AI-assisted overview
The day featured a mix of corporate actions, including multiple Nasdaq delisting notices for Senti Biosciences, Triller Group, and Eureka Acquisition, and a failed Phase 3 trial for Ultragenyx's Angelman syndrome candidate. On the M&A front, INNOVATE closed the sale of a controlling stake in its broadcasting segment to CONX, and G-III completed its $500M acquisition of Marc Jacobs while raising guidance. Five Below reported strong Q2 results and raised its outlook, while Capital Southwest expanded its credit facility. Viking Acquisition shareholders approved a merger with NorthStar despite high redemptions, and Twinlab subsidiaries assigned assets to creditors with no recovery expected for equity holders.
SNTI
Senti Biosciences, Inc.
regulatory
negative
materiality 0.85
September 2, 2026, 4:29 PM ET
Senti Bio receives Nasdaq delisting notices; amends financing, $2M NSG note sale
- Nasdaq: bid price below $1.00 for 30 days; 180-day cure period to Feb 23, 2027.
- Stockholders' equity deficit of $3.4M vs $2.5M requirement; plan due Oct 11, 2026.
- Amendment authorizes $2.0M third-tranche note sale to NSG BioInnovation Fund.
M&A
positive
materiality 0.90
September 2, 2026, 4:18 PM ET
INNOVATE closes sale of 75% controlling interest in Broadcasting segment to CONX
- CONX acquires 75% of HC2 (Broadcasting segment); INNOVATE retains 25% stake, subject to post-closing adjustments.
- CONX commits up to $75M equity to HC2; ~$3.7M funded at closing, remainder payable later.
- $105M bridge loan and accrued interest extinguished at closing.
GIII
G III APPAREL GROUP LTD /DE/
M&A
positive
materiality 0.90
September 2, 2026, 7:30 AM ET
G-III closes $500M Marc Jacobs acquisition; Q2 GAAP EPS $0.46, raises FY27 guidance
- Closed acquisition of Marc Jacobs from LVMH on Sept 1, 2026; $500M investment funded by cash and revolver.
- Formed 50/50 JV with WHP Global to own Marc Jacobs IP; G-III operates business under license through Dec 2041.
- Q2 net sales $554.1M, down 10% YoY; gross margin 45.2% up 440bps; GAAP EPS $0.46 vs $0.25.
regulatory
negative
materiality 0.80
September 2, 2026, 5:00 PM ET
Triller Group receives Nasdaq delisting notice for MVLS below $35M; disputes Panel authority
- On Aug 27, 2026, Nasdaq notified Triller its MVLS fell below $35M minimum for 30 consecutive business days through Aug 25, 2026.
- Company has 7 days to submit a compliance plan to Nasdaq Hearings Panel; intends to do so.
- Panel previously retained discretionary jurisdiction through Oct 14, 2026; company disputes legality and sent letter Aug 26, 2026.
VACI
Viking Acquisition Corp I
M&A
negative
materiality 0.80
September 2, 2026, 4:06 PM ET
Viking Acquisition shareholders approve NorthStar merger; 22.17M Class A shares seek redemption
- All proposals passed at Sep 2 EGM: Continuation, Business Combination (20,358,376 for vs 1,173,543 against), NYSE, incentive plan, advisory items.
- Preliminary redemptions: 22,171,711 of 23,660,000 Class A shares (93.7%) seek redemption as of Sep 2; subject to withdrawal with Viking's consent.
- Closing of NorthStar deal remains subject to NYSE listing approval and other conditions; final redemption amounts to be disclosed after closing.
EURK
Eureka Acquisition Corp
regulatory
negative
materiality 0.75
September 2, 2026, 8:30 AM ET
Eureka Acquisition Corp receives Nasdaq delisting notices for public float and MVLS deficiencies
- On Aug 27, 2026, Nasdaq notified Eureka it no longer meets 500,000 publicly held shares (Rule 5550(a)(4)).
- Same day, Nasdaq notified MVLS below $35M for 30 consecutive business days (Rule 5550(b)(2)).
- Company has until Oct 12, 2026 to submit plan for public float; 180 days (to Feb 23, 2027) for MVLS compliance.
RARE
Ultragenyx Pharmaceutical Inc.
other material
negative
materiality 1.00
September 2, 2026, 4:04 PM ET
Ultragenyx Phase 3 Aspire fails primary and key secondary endpoints in Angelman syndrome
- Apazunersen (GTX-102) did not meet primary endpoint (Bayley-4 cognitive raw score change) nor key secondary (MDRI net response).
- No differences vs control on Bayley Cognition raw scores or MDRI mean changes across five individual endpoints.
- Safety profile in Aspire consistent with Phase 1/2; randomized groups comparable at baseline.
—
TWINLAB CONSOLIDATED HOLDINGS, INC.
other material
negative
materiality 1.00
September 2, 2026, 11:02 AM ET
Twinlab subsidiaries assign assets to creditors; sale to cbdMD for $3.98M; no shareholder recovery expected
- Three Twinlab subsidiaries (TCC, THI, OH) made assignments for benefit of creditors on Aug 21, 2026; petitions filed Aug 24 in Broward County, FL.
- Asset Purchase Agreement with cbdMD: $3,979,805 price, incl. $1.75M secured note assumption and 2,229,805 cbdMD shares (19.9%) to Akretive.
- Akretive holds $67.5M secured and $79M unsecured claims; TCC scheduled $80.9M unsecured debt; no recovery expected for equity holders.
earnings
positive
materiality 0.90
September 2, 2026, 4:17 PM ET
Five Below Q2 comp +14.1%, adjusted EPS $1.68; raises FY26 outlook, new $600M buyback
- Q2 net sales $1.26B (+22.9% YoY); comp sales +14.1%; 52 net new stores, ending at 2,022.
- GAAP diluted EPS $3.99; adjusted EPS $1.68 vs $0.81 a year ago; GAAP includes tariff refunds.
- FY26 guidance raised: net sales $5.63-5.71B (prior $5.40-5.48B); comp +10-12%; adjusted EPS $9.83-10.31.
CSWC
CAPITAL SOUTHWEST CORP
debt
positive
materiality 0.75
September 2, 2026, 5:21 PM ET
Capital Southwest ups credit facility to $595M, cuts margin to 2.00%, extends maturity to 2031
- Revolver commitments raised from $510M to $595M; accordion increased from $750M to $1B.
- Final maturity extended from Aug 2028 to Sept 2031; revolving period to Sept 2030.
- Applicable margin cut from 2.15% to 2.00% and SOFR adjustment removed.